For most of recorded history, human life expectancy climbed steadily, and globally it continues to do so. But the trend is no longer uniform. Some countries have seen gains stall or even reverse, the COVID-19 pandemic knocked years off life expectancy in dozens of nations, and widening inequality means the answer to “is life expectancy increasing?” depends heavily on where you live, how much money you make, and what year you’re asking about. The long arc still points upward, yet the trajectory has become far less predictable than it was a generation ago.
How We Got Here
The dramatic rise in life expectancy over the past two centuries is largely a story about not dying young. In the United States, mortality rates fell faster during the late nineteenth and early twentieth centuries than during any other period in the country’s history. Much of that progress came from infrastructure, not medicine. Clean water technologies alone were responsible for roughly half of the total mortality reduction in major American cities during the early 1900s, about three-quarters of the decline in infant mortality, and nearly two-thirds of the drop in child deaths.1PubMed. The role of public health improvements in health advances: the twentieth-century United States Sanitation systems, milk purification, and institutional frameworks to monitor infant health all contributed to a transformation that happened before antibiotics or modern surgery existed.2PubMed Central. Learning From History About Reducing Infant Mortality: Contrasting the Centrality of Structural Interventions to Early 20th-Century Successes in the United States to Their Neglect in Current Global Initiatives
This early wave of gains was overwhelmingly about children surviving to adulthood. When infant and child mortality plummets, average life expectancy at birth rises sharply even if adult death rates barely change. That distinction matters because it shapes how we read the numbers. A society where life expectancy jumps from 45 to 75 hasn’t necessarily added 30 years to anyone’s old age. It has mostly stopped losing enormous numbers of people in infancy and childhood.
The shift also changed what people die of. As infectious disease retreated, chronic conditions like heart disease, cancer, and diabetes became the leading causes of death. Every state in India, for example, crossed the threshold where non-communicable diseases caused more lost healthy years than infections did, with the most developed states reaching that point by the mid-1980s and the least developed states following by 2010.3The Lancet. Effects of health transition on disease burden in each state of India This transition from infectious to chronic disease is a pattern that plays out worldwide as countries develop, and it fundamentally changes what determines whether life expectancy keeps climbing.4PubMed Central. Updating the epidemiological transition model
COVID-19 and the First Major Reversal in Decades
The pandemic exposed just how fragile life expectancy gains can be. In 2020, high-income countries experienced drops in life expectancy of a scale not seen in recent memory. Parts of western Europe bounced back by 2021, with life expectancies returning to pre-pandemic levels. But the United States, eastern Europe, and Chile did not recover. Instead, they saw sustained and even worsening deficits into 2021.5PubMed Central. Life expectancy changes since COVID-19
The geographic pattern of recovery tells a story about health-system resilience. Countries with stronger primary care networks and higher vaccination uptake tended to recover faster. Those with pre-existing structural weaknesses, such as high obesity rates, fragmented healthcare access, or heavy substance-use burdens, absorbed the pandemic shock more deeply. COVID-19 didn’t create these vulnerabilities. It amplified them. In low-income countries, the damage was compounded: COVID-19 had a significant negative effect on life expectancy, while low health expenditure and high child mortality rates made recovery even harder.6PubMed Central. Restoring life expectancy in low-income countries: the combined impact of COVID-19, health expenditure, GDP, and child mortality
Why the United States Keeps Falling Behind
Even before COVID-19, the U.S. was an outlier among wealthy nations. American life expectancy stalled and then declined starting around 2014, driven by causes of death that barely register in peer countries. A significant share of the story involves what researchers call deaths of despair: deaths from suicide, alcohol-related causes, and drug overdoses. These disproportionately affect men and have reshaped the gender gap in American longevity. After four decades in which women’s advantage in life expectancy had been narrowing, the gap widened again after 2012, and deaths of despair explain the vast majority of that resurgence.7PubMed Central. The Gender Gap in Life Expectancy in the United States and Deaths of Despair: Trends from 1979 to 2022
The opioid crisis alone accounts for a staggering share of premature death in the U.S. that simply does not exist at the same scale in western Europe or east Asia. When you combine that with declining progress against cardiovascular disease, the result is a country whose life expectancy curve has gone flat or even dipped while its economic peers continued improving. The American anomaly isn’t about genetics or geography. It reflects policy choices around healthcare access, drug regulation, social safety nets, and how a society responds to economic dislocation.
Cardiovascular Progress Has Stalled
For decades, falling rates of heart disease and stroke were the single biggest engine driving life expectancy gains in wealthy countries. Better treatments for heart attacks, widespread statin use, and declining smoking rates all contributed. But that progress hit a wall around 2010 in the United States, and the reasons appear to be pervasive. Rising obesity, increasing diabetes prevalence, and worsening hypertension among American adults have overwhelmed the cardiovascular advantages that certain regions and income groups used to enjoy. The stalling of cardiovascular disease declines is happening across the entire country, even in areas that historically performed well on health metrics.8American Journal of Epidemiology. Pervasive stagnation: flat and increasing cardiovascular disease mortality rates after 2010 across US states and counties
This isn’t just an American problem. Analysis of data from both the U.S. and Australia suggests that overweight and obesity have been key drivers of the recent slowdown or outright reversal of cardiovascular mortality declines in both countries.9PubMed Central. The role of overweight and obesity in adverse cardiovascular disease mortality trends: an analysis of multiple cause of death data from Australia and the USA If cardiovascular disease was the engine of life expectancy gains, obesity is now the sand in the gears. And since obesity rates continue to climb in most high-income countries, there’s no reason to assume cardiovascular mortality will return to its earlier trajectory on its own.
The Income and Education Gap
Averages hide enormous variation. In the United States, adults with a master’s degree or higher had a remaining life expectancy at age 18 that was nearly 15 years longer than those who never finished high school. People living in poverty could expect about ten and a half fewer years than those at four times the poverty line. When you stack every advantage together, the gap becomes staggering: the most socioeconomically advantaged Americans lived roughly 17.5 years longer than the most disadvantaged.10PubMed Central. Marked Disparities in Life Expectancy by Education, Poverty Level, Occupation, and Housing Tenure in the United States, 1997-2014
This pattern holds internationally, though the magnitude varies. Across multiple countries, the gap in life expectancy between the least and most educated adults ranged from about two to eight years for men and up to four and a half years for women.11The Lancet Public Health. Determinants of inequalities in life expectancy: an international comparative study of eight risk factors Research across newer EU member states confirms that both income inequality and education inequality have a measurable negative effect on population life expectancy, while rising GDP per capita pulls in the opposite direction.12PubMed Central. Impact of education and income inequalities on life expectancy: insights from the new EU members
When someone asks whether life expectancy is increasing, the honest answer often depends on which slice of the population you’re looking at. For affluent, well-educated people in stable countries, life expectancy has continued to climb with relatively few interruptions. For the poorest and least-educated, the gains are smaller, more fragile, and in some cases absent entirely.
Living Longer Versus Living Well
Even where life expectancy is rising, a harder question lurks underneath: are those extra years healthy ones? The answer is mixed, and it depends on what country you look at. In the Americas, life expectancy at age 65 rose by about two years between 1990 and 2019, but healthy life expectancy at 65 rose by only about one and a half years. The share of remaining life spent in poor health held stubbornly steady at around 29%, meaning older adults gained time but spent roughly the same fraction of it dealing with disability or illness.13PubMed Central. Life expectancy, healthy life expectancy, and burden of disease in older people in the Americas, 1990–2019: a population-based study
Germany offers a somewhat more encouraging picture. Between 2002 and 2018, both total and healthy life expectancy increased for men and women, and the proportion of remaining life spent without severe health limitations actually rose over time. For German men aged 50, the years expected to be lived with severe physical limitations dropped modestly, from about nine and a half to about nine years over that period. For women, years with severe mental health limitations fell from about seven to about five and a half.14SSM – Population Health. Trends in healthy life expectancy between 2002 and 2018 in Germany – Compression or expansion of health-related quality of life (HRQOL)? This suggests that at least in some contexts, the extra years of life are genuinely better years, not just more time spent unwell. But the German data also show that the improvements become statistically unreliable at the oldest ages, meaning the very elderly may not share in this trend.
What Countries With the Longest Lives Do Differently
Japan consistently ranks at or near the top of global life expectancy, and researchers have spent decades trying to understand why. The answer appears to be a layered combination of policy and culture. On the policy side, Japan introduced low-cost universal health insurance, widespread preventive health screenings, and national legislation targeting non-communicable diseases as early as the 1950s. Workplace stress measurement became institutionalized. On the cultural side, dietary traditions like washoku (traditional Japanese cuisine) emphasize plant-dominant, nutrient-dense meals, and the Confucian-rooted principle of hara-hachi-bu encourages people to stop eating when they feel about 80% full.15PubMed Central. Lifestyle Medicine and Japan’s Longevity Miracle
This isn’t just cultural mythology. A large prospective study tracking tens of thousands of Japanese adults found that closer adherence to Japanese dietary guidelines was associated with a roughly 15% lower risk of death, with the benefit driven especially by lower cardiovascular and cerebrovascular mortality.16BMJ. Quality of diet and mortality among Japanese men and women: Japan Public Health Center based prospective study Japan’s longevity story suggests that life expectancy responds to systemic investment in prevention, not just in treatment after people get sick.
It’s worth noting that the popular concept of “Blue Zones,” regions around the world supposedly harboring unusual concentrations of centenarians, has come under serious scrutiny. Recent investigations suggest that many longevity records in these areas may stem from clerical errors or unreliable vital records rather than genuinely exceptional lifespans.17PubMed Central. Red zones: the true color behind the myth of blue zones geographic longevity Japan’s advantage, by contrast, rests on large-scale national data and well-documented institutional interventions, making it a more credible model.
When Societies Collapse, Life Expectancy Follows
The assumption that life expectancy only moves in one direction is contradicted by recent history. Russia in the early 1990s offers the most dramatic modern example. Between 1990 and 1994, life expectancy for Russian men dropped by over six years, falling from about 64 to under 58. Women lost about three years.18PubMed. Causes of declining life expectancy in Russia This was beyond the peacetime experience of any industrialized country. Multiple factors converged: economic collapse, social instability, surging alcohol consumption, poor nutrition, deterioration of the healthcare system, and widespread psychological stress from the abrupt transition out of the Soviet economy.19World Development. Causes of the Russian mortality crisis: Evidence and interpretations Similar declines occurred across much of the former Soviet Union.20Journal of Economic Perspectives. Autopsy on an Empire: Understanding Mortality in Russia and the Former Soviet Union
The Russian case proved that life expectancy gains are not permanent deposits in a bank. They can be withdrawn, rapidly, when the social and economic systems that underpin them break down. The lesson resonated again during COVID-19, when countries like the U.S. that appeared to have robust healthcare infrastructure still suffered sustained life expectancy losses.
Air Pollution and Climate Change as Emerging Threats
Environmental factors represent a less visible but persistent drag on life expectancy. Air pollution is now estimated to cause excess mortality rivaling or exceeding that of tobacco smoking. Globally, the loss of life expectancy attributable to all ambient air pollution is estimated at about 2.9 years. Eliminating just fossil-fuel emissions would add roughly a year to global average life expectancy; removing all controllable human-caused emissions could add close to two years.21PubMed Central. Loss of life expectancy from air pollution compared to other risk factors: a worldwide perspective Cardiovascular disease is the primary pathway through which air pollution kills.
Climate change introduces a newer and less well-quantified risk. Panel data studies suggest that a one-degree Celsius rise in average annual temperature is associated with a decline in life expectancy at birth of roughly half a year, with the effect compounded when rainfall patterns also shift. The burden appears to fall disproportionately on women.22PLOS Climate. A panel data study on the effect of climate change on life expectancy These projections carry wide uncertainty, but they point in a direction that works against the historical trend of steady improvement. In the most polluted nations, the relationship between particulate matter and life expectancy is stark: higher concentrations of fine particulate pollution are significantly associated with shorter lifespans and higher infant mortality.
Is There a Ceiling on Human Lifespan?
Even if societies solve all their policy and environmental problems, there’s a deeper question: is there a hard biological limit to how long a human being can live? Leading demographers have argued that human lifespan is essentially fixed at a natural ceiling around 122 years, the age reached by Jeanne Calment. Average life expectancy is rising, but the maximum observed lifespan has not clearly budged.23PubMed Central. No limit to maximal lifespan in humans: how to beat a 122-year-old record
Not everyone agrees. A reanalysis of the data used to propose a 125-year upper bound found methodological problems, including age-biased rounding errors and inconsistent sample sizes, that when corrected eliminated the proposed ceiling entirely. That analysis concluded the upper limit of human lifespan is historically flexible and has been increasing over time.24F1000Research. The dynamic upper limit of human lifespan The debate remains genuinely unresolved. Forecasters face enormous uncertainty: life expectancy and maximum lifespan might plateau, or longevity could rise faster than historical trends would suggest.25PubMed Central. Demographic perspectives on the rise of longevity
From a practical standpoint, the ceiling question matters less for most people than the floor. The gap between what well-off populations achieve and what disadvantaged ones experience is far larger than any plausible difference between current maximum lifespan and some future record. Closing that gap would do more for global life expectancy than pushing the biological frontier.
The New Science of Aging Itself
A relatively young field called geroscience is trying to shift the whole conversation by targeting aging as a biological process rather than fighting diseases one at a time. One of the most promising approaches involves senolytic drugs, which selectively eliminate senescent cells. These are cells that have stopped dividing but accumulate in tissues over time, secreting inflammatory signals that damage surrounding healthy tissue. In mice, senolytic treatment improved physical function and extended lifespan, particularly in already-old animals.26PubMed Central. Senolytics Improve Physical Function and Increase Lifespan in Old Age
These drugs have moved into early human clinical trials, initially targeting diseases of aging like Alzheimer’s. The rationale is that since advanced age is the strongest risk factor for neurodegenerative disease, and aging involves interconnected processes at the molecular and cellular levels, targeting one pathway like cellular senescence could produce benefits across multiple age-related conditions simultaneously.27PubMed Central. A geroscience motivated approach to treat Alzheimer’s disease: Senolytics move to clinical trials Whether senolytics will prove safe and effective in humans remains an open question. But the idea represents a genuine conceptual shift: instead of asking how to treat heart disease or cancer or dementia individually, geroscience asks whether you can slow the underlying process that makes all of them more likely as you age. If that works even partially, it could change the shape of life expectancy curves in ways that conventional medicine cannot.
For now, the mundane interventions still matter more. Statins, for instance, can reduce cardiac events in middle-aged and older adults with enough remaining life expectancy to benefit, but even long-term follow-up of statin trials in high-risk elderly patients has not demonstrated an overall reduction in mortality. A trial following older patients for an average of nearly nine years found a 20% reduction in coronary deaths, but that benefit was offset by trends toward increased stroke deaths and other cardiovascular deaths, resulting in no net survival gain.28PLOS ONE. Long-Term Effects of Statin Treatment in Elderly People: Extended Follow-Up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) The honest reality is that no single drug has added years to average lifespan the way clean water and sanitation did a century ago. The next leap in life expectancy, if it comes, will probably require something more fundamental, whether that’s geroscience breakthroughs, environmental cleanup, or the kind of systemic public health investment that made the twentieth century’s gains possible in the first place.